Supported by Stiftung OPOS zugunsten Wahrnehmungsbehinderten, St. Gallen; Fonds zur Verhinderung von Blindheit, Zürich (CB); the Birdshot Research Fund at Johns Hopkins School of Medicine (JET); the Skirball Foundation, New York, NY, USA (GNH); and Research to Prevent Blindness, Inc., New York, NY, USA (RDL, DAG, GNH).
Disclosure: C. Böni, AbbVie, Inc. (C), Novartis AG (C), Bayer AG (R); J.E. Thorne, Allergan, Inc. (F), AbbVie, Inc. (C), Gilead Sciences Inc. (C), NightstaRx (C), Santen Inc. (C); R.F. Spaide, Topcon Medical Systems, Inc. (C, R); T.A. Ostheimer, None; D. Sarraf, Bayer AG (C), Genentech, Inc. (C), Novartis International AG (C), Optovue, Inc. (C), Allergan, Plc. (F), Heidelberg Engineering, Inc. (F), Genentech, Inc. (F), Optovue, Inc. (F), Regeneron Pharmaceuticals, Inc. (F); R.D. Levinson, None; D.A. Goldstein, Santen Inc. (S), XOMA (US) LLC. (S), Clearside Biomedical, Inc. (S), Allergan, Plc. (S), Abbvie, Inc. (S); L.M. Rifkin, Abbvie, Inc (S); A.T. Vitale, Aciont, Inc. (C), Abbvie, Inc. (C); G.J. Jaffe, AbbVie, Inc. (C), Heidelberg Engineering, Inc. (C); G.N. Holland, AbbVie, Inc. (S), Genentech, Inc. (S), Novartis International AG (S), Santen, Inc. (S), XOMA (US) LLC. (S)